Multiplexed SAA-ELISA Assay for Quantifying Alpha-Synuclein Oligomers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tools for Parkinson's disease and related neurodegenerative disorders like dementia with Lewy bodies and multiple system atrophy lack robust biomarkers for monitoring disease progression and distinguishing between these conditions, with existing assays being either non-quantitative or unable to differentiate between them.
Innovation Solution
Combining seed amplification assays (SAAs) with oligomer-specific enzyme-linked immunosorbent assays (ELISAs) to detect and quantify αSyn aggregates, providing a method for monitoring disease progression and severity by measuring αSyn oligomers in samples such as cerebrospinal fluid or brain homogenates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If seed amplification assays (SAAs) are used to detect αSyn aggregates, then detection sensitivity is improved, but the ability to provide quantitative information and distinguish between different synucleinopathies deteriorates
Solution Approach 1:
The patent combines seed amplification assays (SAAs) with oligomer-specific ELISA assays into a multiplexed assay system. The SAA component provides sensitive detection of αSyn aggregates through seed-mediated amplification, while the ELISA component simultaneously provides quantitative measurement of oligomeric forms. This merging allows the system to achieve both high detection sensitivity and quantitative capability, resolving the contradiction between these two features.
2Ease of operation
If ELISA is used to measure αSyn concentration, then simplicity and speed are improved, but detection capability deteriorates when analyte concentration is below the limit of quantification
Solution Approach 1:
The multiplexed assay merges ELISA with SAA to create a hybrid system where each method compensates for the other's limitations. ELISA provides simplicity, speed, and ease of operation for routine measurements, while SAA provides enhanced detection capability for low-concentration analytes through its seed-mediated amplification mechanism. The combination allows the system to maintain operational simplicity while overcoming the detection limit barrier.
3Ease of operation
If αSyn test alone is used for diagnosis, then ease of operation is improved, but reliability deteriorates as it cannot distinguish between different synucleinopathies
Solution Approach 1:
The assay segments the detection process into distinct components: the SAA segment detects and amplifies αSyn aggregates with high sensitivity, while the ELISA segment specifically quantifies oligomeric forms that are pathologically relevant. This segmentation allows the system to maintain ease of operation as a single integrated assay while improving diagnostic reliability through the ability to detect and quantify specific pathological forms of αSyn that distinguish between different synucleinopathies.
4Ease of operation
If binary SAA tests are used, then ease of operation is improved, but loss of information deteriorates as no information about disease progression is provided
Solution Approach 1:
The multiplexed assay merges the binary detection capability of SAA with the quantitative measurement capability of ELISA. The SAA component provides a clear positive/negative indication of αSyn aggregate presence, maintaining ease of operation. Simultaneously, the ELISA component provides quantitative data on oligomer levels that can be used to track disease progression and monitor treatment responses. This combination eliminates the information loss inherent in binary tests while preserving operational simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination allows for early and quantitative discrimination between control and diseased groups, offering a robust diagnostic tool that correlates with clinical features and disease severity, enhancing the ability to monitor progression and differentiate between Parkinson's disease and other synucleinopathies.
Implementation Method 1
seed amplification assays (SAAs) to detect αSyn disease-associated aggregates
Implementation Method 2
measuring the amount of αSyn in the sample of step (i) with an enzyme linked immunosorbent assay (ELISA)
Data Source
AI summary
The instant disclosure relates to methods for measuring disease progression in Parkinson's Disease and other neurodegenerative diseases.